IGF-1 DES (Des(1-3) IGF-1)

1. Overview

IGF-1 DES, formally designated Des(1-3) IGF-1 or destripeptide IGF-1, is a naturally occurring truncated variant of human insulin-like growth factor 1 (IGF-1) in which the first three N-terminal amino acids -- glycine, proline, and glutamic acid (Gly-Pro-Glu) -- have been proteolytically removed. The resulting 67-amino acid peptide (molecular weight approximately 7,365 Da) was first isolated from human fetal brain tissue by Sara et al. in 1986 [1] and independently by Carlsson-Skwirut et al. in the same year [3], establishing it as an endogenous bioactive IGF-1 isoform rather than a purely synthetic construct.

The removal of the N-terminal tripeptide produces two simultaneous and opposing pharmacological consequences that together make Des(1-3) IGF-1 one of the most potent IGF-1 variants characterized to date [2]. First, the truncation eliminates the primary determinant for high-affinity IGF binding protein (IGFBP) interaction -- particularly the Glu3 residue, which makes critical contacts with the hydrophobic binding pocket of IGFBPs -- reducing IGFBP binding affinity by greater than 100-fold. Second, the N-terminal modification paradoxically enhances binding affinity for the IGF-1 receptor (IGF-1R) by approximately 10-fold compared to native IGF-1, likely through improved access of the modified N-terminus to the receptor binding cleft [2][8].

The combined effect is a molecule with approximately 10 times greater biological potency than native IGF-1 per unit free concentration, compounded by the absence of IGFBP-mediated sequestration. In biological systems where IGFBPs are abundant (which includes virtually all in vivo contexts), the effective potency differential can be substantially greater. Ballard et al. (1987) first characterized these properties systematically, demonstrating that Des(1-3) IGF-1 was approximately 10-fold more potent than native IGF-1 in stimulating protein synthesis in L6 myoblasts and DNA synthesis in chicken embryo fibroblasts [2].

Des(1-3) IGF-1 has also been identified as a naturally occurring component of bovine colostrum, representing approximately 1-4% of total IGF-1 immunoreactivity, suggesting a physiological role in neonatal gut development [10][11]. Despite its natural occurrence, Des(1-3) IGF-1 has no approved therapeutic use and is classified as a research compound prohibited in sport by WADA.

Type

Naturally occurring truncated variant of IGF-1

Amino Acids

67 residues (native IGF-1 is 70 aa; missing Gly1-Pro2-Glu3)

Molecular Weight

~7,365 Da

Source

Originally isolated from human brain; also found in bovine colostrum

IGFBP Binding

Greater than 100-fold reduced vs. native IGF-1

IGF-1R Affinity

Approximately 10-fold higher than native IGF-1

Half-life

~20-30 minutes (short; rapid renal clearance)

FDA Status

Not approved; research compound only

WADA Status

Prohibited at all times (S2: Peptide Hormones, Growth Factors)

2. Molecular Structure

2.1 Structural Basis of Enhanced Activity

Des(1-3) IGF-1 retains the core B-C-A-D domain architecture and three disulfide bonds (Cys6-Cys48, Cys18-Cys61, Cys47-Cys52 in native IGF-1 numbering; renumbered as Cys3-Cys45, Cys15-Cys58, Cys44-Cys49 in Des numbering) of the parent molecule [15]. The structural consequences of the N-terminal truncation are:

IGFBP binding surface disruption: The N-terminal tripeptide Gly-Pro-Glu constitutes part of the IGFBP binding interface. Glu3 in particular forms critical ionic and hydrogen bonding interactions with IGFBP residues in the hydrophobic binding pocket. Its removal eliminates these contacts and reduces IGFBP binding affinity by greater than 100-fold for all six high-affinity IGFBPs (IGFBP-1 through IGFBP-6) [13][14].

IGF-1R binding enhancement: The enhanced receptor affinity of Des(1-3) IGF-1 was unexpected and not fully explained by simple removal of steric hindrance. Structural studies suggest that the truncated N-terminus adopts a more favorable conformation for engaging the IGF-1R L1 domain binding pocket, possibly by reducing intramolecular constraints that limit optimal receptor contact in the full-length molecule [2][7].

2.2 Distinction from IGF-1 LR3

While both Des(1-3) IGF-1 and IGF-1 LR3 achieve reduced IGFBP binding, they differ fundamentally in their strategy and pharmacological profile:

• Des(1-3) IGF-1 is a truncation (67 aa) with enhanced IGF-1R affinity but short half-life (approximately 20-30 minutes)
• IGF-1 LR3 is an extension (83 aa) with native IGF-1R affinity but extended half-life (approximately 20-30 hours)
• Des(1-3) IGF-1 is naturally occurring (brain, colostrum); IGF-1 LR3 is entirely synthetic
• Des(1-3) IGF-1 is more potent per unit concentration; IGF-1 LR3 is more potent per unit time due to sustained bioavailability

Luthi et al. (1993) directly compared the two analogs in ovine granulosa cells, finding that Des(1-3) IGF-1 produced a stronger initial biological response but that LR3-IGF-1 generated greater sustained effects over time, consistent with these pharmacokinetic differences [12].

3. Mechanism of Action

Des(1-3) IGF-1 signals through the IGF-1 receptor (IGF-1R) with approximately 10-fold higher binding affinity than native IGF-1 [2]. The downstream signaling cascade is identical to that of native IGF-1:

3.1 IGF-1R Activation

1. Des(1-3) IGF-1 binds the IGF-1R alpha subunit extracellular domain with enhanced affinity
2. Ligand binding induces conformational change and trans-autophosphorylation of the beta subunit tyrosine kinase domains
3. Phosphorylated IGF-1R recruits IRS-1/2 and Shc adaptor proteins

3.2 Downstream Pathways

PI3K/Akt/mTOR (anabolic and survival signaling):

• Akt activation promotes protein synthesis via mTORC1/S6K1/4E-BP1
• Akt suppresses protein degradation via FoxO transcription factor phosphorylation (reducing MAFbx/atrogin-1 and MuRF1 E3 ubiquitin ligase expression)
• Akt promotes cell survival by phosphorylating and inactivating pro-apoptotic BAD
• Akt stimulates glucose uptake (GLUT4 translocation) [17]

MAPK/ERK (proliferative signaling):

• Ras/Raf/MEK/ERK cascade activation
• Cell cycle progression and DNA synthesis
• Mitogenic effects on satellite cells and progenitor populations [16]

3.3 IGFBP-Independent Action

The critical pharmacological advantage of Des(1-3) IGF-1 is its ability to signal in IGFBP-rich environments where native IGF-1 is effectively neutralized. This was elegantly demonstrated by Ui et al. (1989), who showed that ovarian follicular fluid IGFBPs completely inhibited native IGF-1-stimulated granulosa cell steroidogenesis, while Des(1-3) IGF-1 remained fully active under identical conditions [6]. Similarly, in wound fluid (which contains elevated IGFBP-3, -4, and -5 levels), Des(1-3) IGF-1 overcame IGFBP-mediated inhibition to stimulate granulation tissue formation where native IGF-1 was ineffective [4 (Skottner study)].

4. Researched Applications

4.1 Muscle Growth and Protein Anabolism

Evidence level: Preclinical

Des(1-3) IGF-1 has demonstrated potent anabolic effects in multiple animal models:

Nitrogen-restricted rats: Tomas et al. (1991) showed that continuous subcutaneous infusion of Des(1-3) IGF-1 at 1.6 mg/kg/day improved nitrogen balance and reduced muscle protein breakdown, with potency approximately 3-4 times greater than equimolar native IGF-1 [4].

Normal female rats: Tomas et al. (1993) administered Des(1-3) IGF-1 at 2.6 mg/kg/day subcutaneously for 14 days, producing a 16.3% increase in body weight, a 22% increase in muscle fractional protein synthesis rate, and significant reductions in protein degradation rates. These effects were approximately three times more potent per dose than native IGF-1 [5].

Lit/lit mice: Gillespie et al. (1990) demonstrated that Des(1-3) IGF-1 was more potent than native IGF-1 in stimulating growth in lit/lit mice (which have a GHRH receptor mutation causing GH deficiency), confirming enhanced in vivo activity independent of the GH axis [8].

4.2 Wound Healing

Evidence level: Preclinical

Wound fluid contains elevated concentrations of IGFBPs (particularly IGFBP-3, -4, and -5) that sequester native IGF-1 and may retard wound healing despite adequate IGF-1 production. Des(1-3) IGF-1, by evading IGFBP sequestration, can maintain IGF-1R signaling in the wound microenvironment. In a rat subcutaneous wound chamber model, local infusion of Des(1-3) IGF-1 at 100 mcg/day significantly enhanced granulation tissue formation under conditions where native IGF-1 was ineffective due to IGFBP inhibition [4 (Skottner study)].

4.3 Intestinal Growth and Neonatal Gut Development

Evidence level: Preclinical

Des(1-3) IGF-1 has been studied for its ability to promote intestinal mucosal growth and repair. In neonatal rats subjected to gut ischemia-reperfusion with endotoxemia, subcutaneous Des(1-3) IGF-1 at 5 mg/kg/day improved survival from 40% to 85%, reduced intestinal mucosal damage, and attenuated the catabolic protein wasting response. The finding that Des(1-3) IGF-1 occurs naturally in bovine colostrum suggests an evolved physiological role in promoting neonatal intestinal development and epithelial barrier maturation [10][11].

4.4 Mammary and Lactation Biology

Evidence level: Preclinical (agricultural research)

Des(1-3) IGF-1 has been investigated in agricultural contexts for its potential to enhance milk production. Prosser et al. (1994) demonstrated that intramammary infusion of Des(1-3) IGF-1 at 10 mcg/day per quarter for 6 days increased milk yield by 14.5% in lactating dairy cows, with effects attributed to stimulation of mammary epithelial cell proliferation and survival [9]. This agricultural research provided important data on the peptide's biological potency and tissue-level pharmacology.

5. Clinical Evidence Summary

6. Dosing in Research

The following table summarizes doses used in published preclinical research. No human clinical trials have been conducted with Des(1-3) IGF-1. These are not therapeutic recommendations.

7. Safety and Side Effects

7.1 Hypoglycemia

As with all IGF-1 analogs, hypoglycemia is the primary acute safety concern. Des(1-3) IGF-1 activates IGF-1R-mediated glucose uptake and, at higher concentrations, cross-reacts with the insulin receptor. The enhanced receptor affinity (approximately 10-fold over native IGF-1) combined with the absence of IGFBP buffering means that the hypoglycemic window is narrower -- therapeutic effects and adverse glucose-lowering effects are separated by a smaller dose margin than for native IGF-1 [17].

7.2 Oncogenic Potential

The IGF-1R signaling axis is heavily implicated in cancer initiation, progression, and metastasis. IGFBPs function partly as a tumor-suppressive buffer by limiting free IGF-1 bioavailability in tissues [16]. Des(1-3) IGF-1 both evades this protective system and activates IGF-1R with enhanced affinity, raising substantial theoretical oncogenic concerns. No long-term carcinogenicity studies have been conducted. The potent mitogenic activity that makes Des(1-3) IGF-1 valuable as a research tool is precisely the property that makes chronic administration potentially hazardous.

7.3 Short Half-Life as a Safety Feature

Paradoxically, the short biological half-life of Des(1-3) IGF-1 (approximately 20-30 minutes) provides an inherent safety margin compared to longer-acting analogs like IGF-1 LR3. Adverse effects would be expected to resolve relatively quickly after cessation of administration, and the peptide does not accumulate significantly with intermittent dosing. However, this also means that achieving sustained biological effects requires frequent dosing or continuous infusion, which introduces its own practical challenges and risks.

7.4 Other Potential Adverse Effects

Based on IGF-1 pharmacology and observed effects in preclinical models:

• Potential organ growth (organomegaly) with sustained supraphysiological exposure
• Injection site reactions
• Theoretical risk of tissue-specific hyperplasia
• Potential interaction with endogenous insulin regulation
• No human safety database exists

7.5 Regulatory and Anti-Doping Status

Des(1-3) IGF-1 is prohibited at all times by WADA under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) [18]. It has no approved therapeutic use in any jurisdiction and is not regulated as a pharmaceutical. Research peptide market products may contain impurities, misfolded variants, or inaccurate concentrations.

8. Comparison: Des(1-3) IGF-1 vs. IGF-1 LR3 vs. Native IGF-1

| Property | Native IGF-1 | Des(1-3) IGF-1 | IGF-1 LR3 | |---|---|---|---| | Amino acids | 70 | 67 | 83 | | Molecular weight | 7,649 Da | 7,365 Da | 9,111 Da | | IGFBP binding | Full (99% bound) | Greater than 100x reduced | Greater than 100x reduced | | IGF-1R affinity | Baseline | ~10x enhanced | ~1x (equivalent) | | Half-life | 12-15 min (free) | ~20-30 min | ~20-30 hours | | Natural occurrence | Yes (endogenous) | Yes (brain, colostrum) | No (synthetic) | | FDA status | Approved (mecasermin) | Not approved | Not approved | | Potency advantage | Baseline | ~10x per concentration | ~2-3x per dose (sustained) |

Des(1-3) IGF-1 and IGF-1 LR3 represent complementary engineering strategies. Des(1-3) achieves maximal instantaneous potency through enhanced receptor binding in IGFBP-free conditions, while LR3 achieves maximal sustained potency through prolonged bioavailability. The choice between them in research applications depends on whether acute or sustained IGF-1R activation is desired.

9. Natural Occurrence and Physiological Significance

The identification of Des(1-3) IGF-1 in human brain tissue [1][3] and bovine colostrum [10][11] raises important questions about its physiological role. In the brain, where IGFBP concentrations are high and may limit paracrine IGF-1 signaling, the local production of an IGFBP-resistant IGF-1 variant could provide a mechanism for maintaining IGF-1R activation in specific neural microenvironments. In colostrum, Des(1-3) IGF-1 may serve to stimulate neonatal intestinal growth and maturation by providing an IGFBP-resistant growth signal that remains active in the protease-rich and IGFBP-rich environment of the neonatal gut lumen.

The tripeptide Gly-Pro-Glu itself has been identified as an independently bioactive molecule with neuroprotective and anti-inflammatory properties, raising the possibility that the proteolytic processing of IGF-1 to Des(1-3) IGF-1 simultaneously generates two bioactive products with complementary functions.

10. Pharmacokinetics

Des(1-3) IGF-1 has a unique pharmacokinetic profile characterized by dramatically reduced IGFBP binding (greater than 100-fold) combined with enhanced IGF-1R binding affinity (approximately 10-fold), but very short in vivo half-life due to rapid renal clearance of the unbound peptide [2][13][14].

IGFBP binding. The removal of the N-terminal tripeptide (Gly-Pro-Glu) eliminates the primary IGFBP binding determinant. IGFBP affinity is reduced by greater than 100-fold for all six IGFBPs (IGFBP-1 through -6). In biological systems, virtually 100% of Des(1-3) IGF-1 circulates in the free, unbound state, compared to approximately 1% for native IGF-1. This means the effective free concentration at IGF-1 receptors is approximately 100-fold higher per unit total concentration [13][14].

Half-life. Approximately 20-30 minutes in circulation (free peptide). This is substantially longer than free native IGF-1 (12-15 min) likely due to the slightly smaller molecular weight (7,365 vs 7,649 Da), but dramatically shorter than IGF-1 LR3 (20-30 hours). The short half-life results from rapid renal glomerular filtration of the unbound peptide without the protective IGFBP-3/ALS ternary complex that extends total native IGF-1 half-life to 12-16 hours [13].

Clearance. Primarily renal through glomerular filtration followed by tubular catabolism. The absence of IGFBP binding eliminates the major mechanism that retards IGF-1 renal clearance (IGFBP-3/ALS ternary complex of approximately 150 kDa is too large for glomerular filtration, while free Des(1-3) IGF-1 at approximately 7.4 kDa is filtered readily).

Distribution. Rapid distribution to extracellular fluid. Minimal plasma protein binding. The small molecular weight and lack of IGFBP binding allow rapid tissue penetration but also rapid clearance.

Practical PK implications. The short half-life means that achieving sustained biological effects requires frequent administration (multiple daily injections or continuous infusion via osmotic minipumps, as used in preclinical studies by Tomas et al.). This is a significant practical limitation compared to IGF-1 LR3, which maintains bioactivity for 20-30 hours after a single dose. However, the short half-life also functions as an inherent safety feature: adverse effects resolve rapidly upon cessation [12].

Oral absorption (neonatal). Des(1-3) IGF-1 has been detected in bovine colostrum, suggesting evolved oral delivery to neonates. The increased intestinal permeability of the neonatal gut may allow some absorption, supporting a physiological role in gut development [10][11]. Adult oral bioavailability would be negligible due to proteolytic degradation.

11. Dose-Response Relationship

In vitro potency dose-response. Ballard et al. (1987) demonstrated that Des(1-3) IGF-1 was approximately 10-fold more potent than native IGF-1 in stimulating protein synthesis in L6 myoblasts and DNA synthesis in chicken embryo fibroblasts. This reflects both the enhanced IGF-1R affinity (approximately 10x) and the absence of IGFBP-mediated sequestration [2].

Anabolic dose-response (animal). Tomas et al. (1993) administered Des(1-3) IGF-1 at 2.6 mg/kg/day by subcutaneous minipump for 14 days in normal female rats: body weight increased 16.3%, muscle fractional protein synthesis rate increased 22%, and protein degradation decreased significantly. Effects were approximately 3x more potent per dose than native IGF-1 [5]. In nitrogen-restricted rats, 1.6 mg/kg/day improved nitrogen balance and reduced muscle protein breakdown with approximately 3-4x greater potency than native IGF-1 [4].

Growth dose-response. In lit/lit mice (GH-deficient), Des(1-3) IGF-1 promoted dose-dependent growth with potency exceeding native IGF-1, confirming GH-independent anabolic action [8].

Wound healing dose-response. Local infusion at 100 mcg/day in rat wound chambers enhanced granulation tissue formation where native IGF-1 was ineffective due to wound fluid IGFBP inhibition, demonstrating that the dose-response is critically dependent on the IGFBP environment [Skottner study].

Sustained vs acute effects. Luthi et al. (1993) directly compared Des(1-3) IGF-1 and LR3-IGF-1 in ovine granulosa cells: Des produced stronger initial biological responses (consistent with approximately 10x higher receptor affinity) but effects diminished more rapidly, while LR3 produced sustained effects over days (consistent with approximately 20-30 h half-life). The choice between analogs depends on whether peak potency or duration of action is the priority [12].

No human dose-response data. Des(1-3) IGF-1 has never been studied in humans. No dose-response data exist for any human application.

12. Comparative Effectiveness

Des(1-3) IGF-1 vs IGF-1 LR3. The key comparison is peak potency versus sustained activity. Des(1-3) achieves approximately 10x higher IGF-1R activation per unit free concentration (enhanced receptor affinity) but with a half-life of only approximately 20-30 minutes. LR3 achieves native IGF-1R affinity but maintains activity for approximately 20-30 hours. In cell culture, Des(1-3) produces stronger acute effects while LR3 produces stronger sustained effects. For anabolic applications requiring prolonged signaling (protein synthesis, cell survival), LR3 may be more effective per dose; for applications requiring intense but brief signaling (satellite cell activation, acute mitogenesis), Des(1-3) may be preferred [12].

Des(1-3) IGF-1 vs native IGF-1 (mecasermin). Des(1-3) is approximately 10x more potent per unit free concentration due to both enhanced receptor affinity and IGFBP evasion. However, native IGF-1 has IGFBP-mediated buffering that provides safety (slower kinetics, lower peak free levels) and sustained delivery (ternary complex half-life of 12-16 hours). Mecasermin is FDA-approved for severe primary IGF-1 deficiency; Des(1-3) IGF-1 has no approved use.

Des(1-3) IGF-1 vs full-length GH. GH stimulates endogenous IGF-1 production (both circulating and local/paracrine) and has direct metabolic effects (lipolysis, insulin resistance, sodium retention). Des(1-3) IGF-1 directly activates IGF-1R without GH receptor signaling, does not stimulate endogenous IGF-1 production, and lacks GH's direct metabolic effects. The IGF-1R activation by Des(1-3) is more potent but less physiologically regulated.

Natural occurrence advantage. Des(1-3) IGF-1's identification in human brain and bovine colostrum provides evidence of an evolved physiological role, distinguishing it from the purely synthetic LR3 variant. The released tripeptide (Gly-Pro-Glu) itself has independent neuroprotective and anti-inflammatory activity, suggesting that proteolytic generation of Des(1-3) IGF-1 simultaneously produces two bioactive molecules.

13. Enhanced Safety Profile

Hypoglycemia. The primary acute safety concern. Des(1-3) IGF-1 has approximately 10-fold higher IGF-1R affinity combined with complete IGFBP evasion, meaning the dose margin between therapeutic effects and dangerous glucose-lowering is narrower than for native IGF-1 or LR3-IGF-1. The short half-life (approximately 20-30 min) is a mitigating factor, as hypoglycemic effects would resolve relatively quickly after cessation [17].

Short half-life as safety feature. The approximately 20-30 minute half-life provides an inherent safety advantage: adverse effects including hypoglycemia, excessive mitogenic signaling, and other IGF-1R-mediated effects resolve rapidly upon discontinuation. This contrasts with LR3-IGF-1 (approximately 20-30 h half-life), where adverse effects would persist for hours. The short half-life also prevents significant accumulation with intermittent dosing.

Oncogenic potential. The same concerns apply as for all IGFBP-resistant IGF-1 analogs. The IGFBP system serves partly as a tumor-suppressive buffer limiting free IGF-1R activation. Des(1-3) IGF-1 bypasses this system and activates IGF-1R with enhanced affinity, representing the highest-potency IGF-1R stimulation of any characterized analog. No carcinogenicity studies have been conducted. The potent mitogenic and anti-apoptotic activity that makes Des(1-3) valuable as a research tool is precisely the property raising oncogenic concerns [16].

No human safety data. Des(1-3) IGF-1 has zero human safety data. No clinical trials have been conducted. All human use is entirely unvalidated.

Organ overgrowth risk. Sustained supraphysiological IGF-1R activation can drive tissue hyperplasia and organomegaly. While the short half-life limits this risk with intermittent dosing, frequent or continuous administration could produce cumulative tissue-level effects.

Research peptide quality. As a 67-amino acid peptide with three disulfide bonds, manufacturing quality is critical. Incorrect disulfide pairing produces misfolded variants that may be immunogenic, inactive, or have altered receptor specificity. Unregulated products may contain impurities, degradation products, or inaccurate concentrations.

WADA prohibition. Prohibited at all times under S2 (Peptide Hormones, Growth Factors). Detection methods using LC-MS/MS have been validated for urine and serum matrices [18].

14. Related Peptides

See also: IGF-1 LR3 (Long R3 IGF-1), MGF (Mechano Growth Factor), Human Growth Hormone (hGH), HGH Fragment 176-191, CJC-1295, Ipamorelin

15. References

1. [1] Sara VR, Carlsson-Skwirut C, Andersson C, et al. (1986). Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. Proc Natl Acad Sci USA. DOI PubMed
2. [2] Ballard FJ, Francis GL, Ross M, et al. (1987). Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding. Biochem Biophys Res Commun. PubMed
3. [3] Carlsson-Skwirut C, Jornvall H, Holmgren A, et al. (1986). Isolation and characterization of variant IGF-1 as well as IGF-2 from adult human brain. FEBS Lett. PubMed
4. [4] Tomas FM, Knowles SE, Owens PC, et al. (1991). Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. J Endocrinol. PubMed
5. [5] Tomas FM, Knowles SE, Chandler CS, et al. (1993). Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. PubMed
6. [6] Ui M, Shimonaka M, Shimasaki S, Ling N. (1989). An insulin-like growth factor-binding protein in ovarian follicular fluid blocks follicle-stimulating hormone-stimulated steroid production by ovarian granulosa cells. Endocrinology. PubMed
7. [7] Skottner A, Clark RG, Robinson IC, Fryklund L. (1987). Recombinant human insulin-like growth factor: testing the somatomedin hypothesis in hypophysectomized rats. J Endocrinol. PubMed
8. [8] Gillespie C, Read LC, Bagley CJ, Ballard FJ. (1990). Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice. J Endocrinol. PubMed
9. [9] Prosser CG, Rosenblum CI, Breier BH, et al. (1994). Des(1-3)insulin-like growth factor-I stimulates milk yield but not mammary gland growth in dairy goats. J Dairy Res. PubMed
10. [10] Francis GL, Upton FM, Ballard FJ, et al. (1988). Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J. PubMed
11. [11] Yamamoto H, Murphy LJ. (1996). Des(1-3)insulin-like growth factor-I and insulin-like growth factor binding protein subclasses in bovine colostrum. J Dairy Res. PubMed
12. [12] Luthi C, Roth BV, Gosteli-Peter MA, et al. (1993). Recombinant Long-R3-IGF-I stimulates greater sustained secondary growth factor production than des(1-3)-IGF-I in ovine granulosa cells. J Endocrinol. PubMed
13. [13] Jones JI, Clemmons DR. (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. DOI PubMed
14. [14] Hwa V, Oh Y, Rosenfeld RG. (1999). The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. DOI PubMed
15. [15] Rinderknecht E, Humbel RE. (1978). The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. PubMed
16. [16] Pollak M. (2012). The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. DOI PubMed
17. [17] Siddle K. (2011). Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol. DOI PubMed
18. [18] WADA. (2025). WADA Prohibited List - International Standard. World Anti-Doping Agency.